Bevacizumab-induced perforation of the gastrointestinal tract: Clinical and radiographic findings in 11 patients

Abdominal Imaging

Volumn 38, Issue 2, 2013, Pages 265-272

  Borofsky, Samuel E ^a   Levine, Marc S ^a,b   Rubesin, Stephen E ^a,b   Tanyi, Janos L ^a   Chu, Christina S ^a   Lev Toaff, Anna S ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b Bracco Research USA   (United States)

Author keywords

Abdominal CT; Bevacizumab; Fluoroscopic gastrointestinal contrast studies; Gastrointestinal perforation

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOFOS; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LANTHANUM; LETROZOLE; OXALIPLATIN; PACLITAXEL; THALIDOMIDE; TOPOTECAN;

ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; COLORECTAL ANASTOMOSIS; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG HALF LIFE; DRUG INDUCED DISEASE; ENTEROCUTANEOUS FISTULA; FOLLOW UP; GASTROINTESTINAL TRACT; HUMAN; INTESTINE PERFORATION; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UTERINE CERVIX CANCER;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTESTINAL FISTULA; INTESTINAL PERFORATION; MULTIDETECTOR COMPUTED TOMOGRAPHY; OVARIAN NEOPLASMS; RADIOGRAPHY, ABDOMINAL; RETROSPECTIVE STUDIES; VAGINAL FISTULA;

EID: 84879502599     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-012-9913-3     Document Type: Article

References (30)

1. Horn L, Sandler A (2007) Chemotherapy and antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer 8(suppl 2):S68-S73
2. Ranieri G, Patruno R, Ruggieri E, et al. (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic [Review]. Curr Med Chem 13:1845-1857
3. Homsi J, Daud AI (2007) Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 14:285-294
4. Van Cutsem E, Rivera F, Berry S, et al. (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842-1847
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
6. Sandler A, Gray R, Perry MC, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
7. Miller K, Wang M, Gralow J, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
8. Sparano JA, Gray R, Giantonio B, et al. (2004) Evaluating antiangiogenesis agents in the clinic: the eastern cooperative oncology group portfolio of clinical trials. Clin Cancer Res 10:1206-1211
9. Ley EJ, Vukasin P, Kaiser AM, et al. (2007) Delayed rectovaginal fistula: a potential complication of bevacizumab (avastin) [Letter]. Dis Colon Rectum 50:930
10. Chéreau E, Stefanescu D, Selle F, et al. (2009) Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report. Am J Obstet Gynecol 200:e15-e16
11. Gordon MS, Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69(suppl 3):25-33
12. Garcia AA, Hirte H, Fleming G, et al. (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76-82
13. Badgwell BD, Camp ER, Feig B, et al. (2008) Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19:577-582
14. Vincenzi B, Santini D, Russo A, et al. (2009) Bevacizumab in association with de gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. Cancer 115:4849-4856
15. Monk BJ, Sill MW, Burger RA, et al. (2009) Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 27:1069-1074
16. Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis [Review]. Lancet Oncol 10:559-568
17. Cannistra SA, Matulonis UA, Penson RT, et al. (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186
18. Wright JD, Hagemann A, Rader JS, et al. (2006) Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107:83-89
19. Nimeiri HS, Oza AM, Morgan RJ, et al. (2008) Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110:49-55
20. Skillings JR, Johnson DH, Miller K, et al. (2005) Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol 23(suppl 16):3019
21. Zangari M, Fink LM, Elice F, et al. (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27:4865-4873
22. Scappaticci F, Fehrenbacher L, Cartwright T, et al. (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173-180
23. Goodgame B, Veeramachaneni N, Patterson A, et al. (2008) Tracheo-esophageal fistula with bevacizumab after mediastinal radiation. J Thorac Oncol 3:1080-1081
24. Spigel DR, Hainsworth JD, Yardley DA, et al. (2010) Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 28:43-48
25. Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14:1860-1869
26. Wolf I, Urban D, Pfeffer R, et al. (2007) High incidence of fistula formation during bevacizumab treatment in rectal cancer patients [Letter]. Acta Oncol 46:550-553
27. Gressett SM, Shah SR (2009) Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43:490-501
28. Tarnawski AS (2005) Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 50(suppl 1):S24-S33
29. Heinzerling JH, Huerta S (2006) Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 63:334-347
30. Tol J, Cats A, Mol L, et al. (2008) Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs 26:393-397